Key Notes
- Johnson & Johnson reported adjusted EPS of $2.59, exceeding the LSEG estimate of $2.54, on quarterly revenue of $25.4 billion.
- Full-year adjusted EPS guidance rises to $11.05–$11.15, with a midpoint of $11.10, while the sales midpoint increases to $101.2 billion.
- Reported net earnings fell sharply as a talc-litigation charge and recent transactions offset growth in the company’s newer medicines.
Johnson & Johnson (NYSE: JNJ) raised its 2026 outlook after third-quarter adjusted earnings and revenue exceeded analyst expectations, with growth in newer medicines helping offset pressure on its medical-device business. The results leave investors weighing the company’s operating momentum against litigation costs and spending on future treatments.
Adjusted earnings reached $2.59 per share, compared with an LSEG consensus of $2.54, while revenue of $25.4 billion topped the $25.28 billion estimate, Reuters reported. The company’s release put reported sales growth at 5.9%.
The earnings beat came alongside a sharp fall in reported profit. GAAP net earnings declined 95.9% to $210 million, or $0.09 per share, reflecting a special talc-litigation charge and the effects of recent transactions. Adjusted EPS also fell from $2.80 a year earlier, despite exceeding forecasts.
Higher Guidance Sets the Benchmark for JNJ Shares
J&J now expects full-year adjusted EPS of $11.05–$11.15, compared with $10.96–$11.11 previously. The midpoint rises by six cents to $11.10. Its reported-sales forecast is $101.0 billion–$101.4 billion, with a $101.2 billion midpoint, up from $101.1 billion.
The company separately forecasts adjusted operational EPS of $10.95–$11.05. That measure excludes currency translation and should not be confused with the higher adjusted-EPS range. Neither is a forecast of GAAP earnings.
For shareholders, the improvement in guidance and the year-over-year decline in quarterly earnings answer different questions. The first changes management’s expectations for the full year; the second shows what happened to profit during the quarter. An earnings beat means the result exceeded forecasts, not that profit necessarily grew.
Tremfya Helps Offset Stelara’s Decline
Pharmaceutical sales rose 7.7% to $16.76 billion. Tremfya sales rose 68% to $2.4 billion, while Stelara fell 54% to $716 million amid competing versions, according to Reuters. Darzalex generated $4.24 billion, up about 16%, but below the $4.4 billion analyst estimate.
That mix is important to the stock’s longer-term earnings case. Replacing revenue lost by a mature medicine requires newer products to gain enough sales to support both growth and the research spending behind subsequent launches. Strong performance by one treatment does not remove pressure elsewhere in the portfolio.
Talc Resolution Carries a Cost and Conditions
The legal backdrop is J&J’s July proposal to resolve remaining ovarian talc claims through a $5.5 billion commitment. The company said the agreement required participation representing at least 95% of the remaining claims, among other conditions.
Under the announced terms, the initial payment would be no more than $3 billion in 2027, with no additional payments due before 2028. J&J continues to dispute the allegations. The proposed agreement remains conditional, and recognizing an accounting charge does not establish that all requirements for the resolution have been completed.
The payment schedule also matters when reading earnings. An expense recognized in a quarter and the cash paid to settle a liability can occur at different times. Investors therefore need to assess the effect on reported profit separately from the timing of future cash outflows.
Firefly Acquisition Still Affects Adjusted Earnings
J&J completed its $1 billion cash acquisition of Firefly Bio on July 29, adding a platform designed to deliver protein-degrading agents through antibody conjugates for cancer treatment. The technology expands its research capabilities, with its future commercial value depending on successful development and regulatory approvals.
The company said the purchase would be accounted for as an asset acquisition, creating approximately $1 billion of in-process research and development expense in the third quarter. It expected dilution of about $0.46 to both adjusted operational EPS and adjusted EPS in 2026, and about $0.08 in 2027.
This is an important limit to the adjusted-earnings label: adjustments do not remove every acquisition-related effect. Firefly’s anticipated dilution was already disclosed in July, providing a baseline against which to assess the latest guidance increase.
MedTech Faces Budget Pressure as OTTAVA Moves Forward
Medical-device sales increased 2.5% to about $8.6 billion. Chief Financial Officer Joe Wolk told Reuters that the Middle East conflict, European austerity and Chinese pricing were weighing on international device sales. He said the conflict had hurt regional sales without yet increasing the company’s costs.
A separate commercial milestone arrived on July 22, when J&J announced FDA De Novo authorization for its OTTAVA surgical robotic system. The authorization covers multiple general-surgery procedures in the upper abdomen, and the company outlined an initial launch with selected American customers.
Authorization creates a route to commercialization, rather than a guarantee of immediate material revenue. Hospital adoption, training and purchasing budgets remain relevant to the pace of deployment. That makes the near-term device environment and the longer-term robotics opportunity distinct parts of the outlook.
Manufacturing Investment Adds a Longer-Term Commitment
J&J’s investment plans extend beyond acquisitions. In March 2025, it announced more than $55 billion of American manufacturing, research and technology investment over the following four years, including four planned new manufacturing facilities.
The program formed part of the industry’s response to pressure for domestic production, as we previously reported. That multiyear program predates these results and represents a longer-term commitment alongside the company’s current operating expenses.
For JNJ shareholders, the next tests are whether newer medicines sustain growth, device demand improves and investments translate into commercial returns. The higher outlook is a positive operating signal, while the reported-profit decline and future legal payments remain part of the same financial picture.
